Cystic Fibrosis Foundation released the following clinical trial alert in June 2020.

June 16, 2020

OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency

Status: Enrolling

Description: This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 30% or greater

Number of Visits: 10

Length of Participation: 8 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04375878